Drugs / rGlucagon
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02951780 | Nov 2016 → Jan 2017 | — | Eli Lilly and Company | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02635243 Comparator | Apr → Nov 2016 | type 1 diabetes mellitus | Sanofi | Withdrawn | No outcome recorded |
| Phase 1 | NCT02625636 Comparator | Dec 2015 → Feb 2016 | type 1 diabetes mellitus | Sanofi | Completed | No outcome recorded |
| Phase 1 | NCT02342314 Comparator | Jan 2015 → Sep 2016 | — | Eli Lilly and Company | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | r-glucagon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02625636 ↗ |
| Route | Subcutaneous | “Administered via SC injection” NCT02342314 ↗ |